Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
MarketBeat
Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments,
NASDAQ:GH